Epidermal Growth Factors (EGFs) Market Size, Share Analysis, Growth Trends and Forecast 2026-2033

Epidermal Growth Factors (EGFs) Market Overview

Epidermal Growth Factors (EGFs) Market reached US$ 1475.65 million in 2025 and is expected to reach US$ 2746.81 Billion by 2033, growing at a CAGR of 7.53 % during the forecast period 2026-2033. 

The epidermal growth factors (EGF) market focuses on biologically active proteins that play a critical role in cell growth, proliferation, and differentiation, widely used in pharmaceuticals, biotechnology, and cosmetic applications. These factors are essential in wound healing, tissue regeneration, and cancer therapeutics, making them increasingly important in modern healthcare and life sciences. The market is witnessing steady growth due to rising demand for advanced biologics, increasing prevalence of chronic wounds and cancer, and expanding applications in regenerative medicine and dermatology.
Additionally, growing interest in anti-aging and skin repair products has significantly boosted the use of EGF in cosmetic formulations. Technological advancements in recombinant DNA technology and protein engineering are further enhancing product efficiency and scalability, supporting market expansion. Increased research and development activities, along with rising investments in biotechnology and personalized medicine, are also contributing to market growth. With expanding therapeutic and cosmetic applications, the epidermal growth factors market is expected to experience sustained growth in the coming years.

For more details on this report – Request for Sample

Epidermal Growth Factors (EGFs) Market Dynamics: Drivers 

Rising demand for anti-aging products

The rising demand for anti-aging products is a major driver for the global epidermal growth factor (EGF) market, fueled by increased consumer awareness of skin health and aging. EGF's ability to promote skin regeneration, enhance cell growth, and improve skin texture makes it a sought-after ingredient in cosmetics like serums, creams, and masks. Social media and celebrity endorsements further amplify consumer interest, boosting market expansion and competition among skincare brands.

Several factors contribute to this demand, including younger generations' awareness of skincare, the desire for a youthful appearance, and the increasing aging population. Consumers seek personalized skincare solutions, and EGF's ability to stimulate collagen production and improve skin elasticity makes it a preferred ingredient in luxury formulations. 

Its versatility has led to adoption across skincare, medical applications, and R&D, with EGF enhancing cell proliferation and stimulating collagen production in anti-aging formulations. The clean beauty trend also fuels interest in EGF, driving innovation in product formulations that prioritize skin health.

For instance, in February 2025, Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorization for subcutaneous (SC) RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for first-line treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC) and as a monotherapy for advanced NSCLC with EGFR exon 20 insertion mutations after platinum-based therapy failure.

Also, in October 2024, the FDA approved Roche's Itovebi (inavolisib) in combination with palbociclib and fulvestrant, for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. All these factors demand the global epidermal growth factor (EGFs) market.

Epidermal Growth Factors (EGFs) Market Dynamics: Restraints

High cost of treatment

The high cost of treatment is a significant impediment to the global epidermal growth factors (EGFs) market. Advanced manufacturing processes and extensive research and development contribute to the elevated prices of these therapies. As a result, many patients, especially those in developing regions, find them unaffordable, which limits market penetration and access across demographics. This financial barrier may also deter healthcare providers from prescribing EGF treatments, thereby curtailing the market's growth potential.

Similarly, the high cost of epidermal growth factor receptor (EGFR) inhibitors, particularly next-generation therapies, can be prohibitively expensive, thereby limiting accessibility, especially in low-income regions or among underinsured populations. The financial burden associated with long-term therapy may lead to lower adoption rates and create disparities in patient access to cutting-edge cancer treatments. The widespread use of EGFR inhibitors is hindered in regions where healthcare resources are limited, which ultimately slows market growth, despite the clinical benefits. Thus, the above factors could be limiting the global epidermal growth factor (EGFs) market's potential growth. 

Epidermal Growth Factors (EGFs) Market Segment Analysis

The global epidermal growth factors (EGFs) market is segmented based on product type, form, application, end-user, and region.

Product Type:

The recombinant EGF product type segment is expected to hold 51.8% of the global epidermal growth factors (EGFs)  market in 2024

The recombinant EGF segment is a crucial and growing component of the global epidermal growth factor (EGF) market. Its production relies on recombinant DNA technology, which ensures high purity and safety levels. This method involves inserting the human EGF gene into a host organism like Escherichia coli, which then produces the EGF protein, allowing for large-scale production with consistent quality, making it ideal for pharmaceutical and cosmetic uses. 

Historically, producing these growth factors via recombinant methods has been challenging, often necessitating complex eukaryotic systems, fusion proteins, or intricate renaturing processes. Recombinant EGF is mainly utilized in pharmaceutical products and advanced skincare, leveraging its effective wound-healing and skin-regenerative properties. It finds application in treating conditions like diabetic foot ulcers, bedsores, and chronic leg ulcers.

 The rising demand for healthy skin further propels its use in anti-aging and skin rejuvenation products. For instance, in September 2024, Core Biogenesis launched Peauvita and Peauforia, two anti-aging skincare ingredients. Peauvita (EGF-oleosome) and Peauforia (FGF2-oleosome) leverage the company's plant biofactory production process, using bioactive compounds from Camelina sativa plants. These factors have solidified the segment's position in the global epidermal growth factors (EGFs) market.

Epidermal Growth Factors (EGFs) Market Geographical Analysis

North America is expected to hold 42.6% of the global epidermal growth factors (EGFs) market in 2024

The North American epidermal growth factor (EGF) market is a dominant force in the global arena, driven by its advanced healthcare infrastructure and robust support for innovative therapies. A strong emphasis on skin health among the population fuels a high demand for EGF-based skincare products. Furthermore, significant investments in research and development ensure access to cutting-edge treatments, and the region's thriving biotechnology sector fosters market growth through innovation.

Contributing factors to the North American EGF market's expansion include a growing preference for minimally invasive cosmetic procedures and an increasing geriatric population, both boosting the demand for EGF-related products. High healthcare expenditure facilitates the adoption of targeted therapies, while ongoing advancements in biotechnology further propel the market. Key players like Johnson & Johnson and Amgen Inc. are actively involved, reinforcing the market through their focus on clinical trials and the adoption of new therapies.

Furthermore, key players in the industry and their product launches & approvals that would drive this global epidermal growth factors (EGFs) market growth. For instance, in December 2024, Johnson & Johnson (J&J) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for a subcutaneous (SC) formulation of amivantamab combined with recombinant human hyaluronidase. 

Also, in August 2024, Johnson & Johnson received FDA approval for RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) as a first-line, chemotherapy-free treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.  Thus, the above factors are consolidating the region's position as a dominant force in the global epidermal growth factor (EGFs) market.

Asia Pacific is expected to hold 18.4% of the global epidermal growth factors (EGFs) market in 2024

The Asia-Pacific (APAC) epidermal growth factors (EGFs) market is seeing considerable expansion, fueled by advancements in biotechnology, a growing elderly population, and a booming cosmetic industry.

Japan's progress in biotechnology significantly boosts the market. The rising geriatric population across APAC increases the demand for advanced medical solutions using growth factors. South Korea's rapidly expanding cosmetic industry, known for luxury and quality at affordable prices, is projected to further increase EGF sales and production.

Furthermore, greater awareness and acceptance of new techniques in countries like China and India are contributing to market growth. Patient assistance programs are expected to drive growth in the epidermal growth factor receptor inhibitors market as pharmaceutical companies and governments launch initiatives to improve treatment access.

Moreover, key players in the industry are product launches and approvals that would drive the global epidermal growth factors (EGFs) market growth. For instance, in August 2024, e'clat, a luxury skincare brand, launched e'clat Regenta in India, a product specifically formulated for women over 50. This anti-aging solution contains EGF, Matrixyl, Retinol, Niacinamide, Hyaluronic Acid, and Ceramide to target concerns of mature skin, such as fine lines, reduced collagen, decreased elasticity, and dryness.

Also, in March 2024, Astellas' VYLOY (zolbetuximab) received approval in Japan from the Ministry of Health, Labour and Welfare (MHLW) as the first CLDN18.2-targeted therapy worldwide for patients with CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer that is also HER2-negative. That is also human epidermal growth factor receptor 2 (HER2)-negative. It is used in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global epidermal growth factors (EGFs) market.

Epidermal Growth Factors (EGFs) Market Major Players

The major global players in the epidermal growth factors (EGFs) market include Thermo Fisher Scientific Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, PeproTech Inc., Bio-Techne Corporation, Abcam plc, Lonza Group AG, GenScript Biotech Corporation, Creative BioMart, Miltenyi Biotec among others.

Key Developments

• In June 2025, Hoth Therapeutics launched an Expanded Access initiative for HT-001 to support cancer patients experiencing severe skin toxicities associated with epidermal growth factor receptor inhibitor therapies. This development reflects growing commercial and clinical focus on targeted supportive-care solutions linked to epidermal growth factor pathway–related treatment complications.
• In January 2025, Johnson & Johnson reported positive topline Phase III MARIPOSA study results showing that RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) significantly improved overall survival in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or L858R substitution mutations.
   

Market Scope